Skip to content
type1.science
Phase 2CompletedNCT01781975

Imatinib in recent-onset type 1 diabetes

Multicenter phase-2 trial of the oral tyrosine kinase inhibitor imatinib in adults within 100 days of diagnosis. It met the 12-month C-peptide endpoint, but the effect was not sustained at 24 months.

Primary endpoints

  • 2-hour mixed-meal stimulated C-peptide AUC at 12 months

Results so far

The trial met its 12-month C-peptide endpoint, but the benefit was not sustained at 24 months after the 26-week course ended.

The full picture

Imatinib is a useful "positive but not enough" trial: C-peptide moved at 12 months, but the signal faded by 24 months and tolerability limits enthusiasm for long-term prevention use.